calendar
69 catalysts · 18 phase 2 initiation · 15 phase 2 completion · 6 phase 1 completion · 4 phase 3 completion · 4 phase 3 initiation · 4 phase 1 2 initiation
next 91 dayslessmore
MonWedFri
69 catalysts · 18 phase 2 initiation · 15 phase 2 completion · 6 phase 1 completion · 4 phase 3 completion · 4 phase 3 initiation · 4 phase 1 2 initiation
Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Therapy area: Oncology. Indication: Non-Small Cell Lung Cancer
Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Solid Tumor
Therapy area: Oncology. Indication: Solid Tumor
Therapy area: Oncology. Indication: Metastatic Pancreatic Cancer, Pancreatic Cancer
Therapy area: Oncology. Indication: Nasopharyngeal Cancer
Therapy area: Oncology. Indication: Hepatocellular Carcinoma, Liver Cancer
Therapy area: Oncology. Indication: Cervical Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer, Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hepatocellular Carcinoma, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Pleural Mesothelioma, Melanoma, Non-Small Cell Lung Carcinoma, Oral Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Re
Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Plasma Cell Neoplasm, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Therapy area: Ophthalmology. Indication: Cataract, Fuchs Endothelial Corneal Dystrophy (FECD)
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma
Therapy area: Oncology, Toxicology. Indication: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome), Colon Tumor
Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer
Therapy area: Genito Urinary System, Oncology. Indication: Bladder Cancer, Bladder Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Transitional (Urothelial) Tract Cancer, Renal Stones/Calculi, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer
Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, Laryngeal Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Recurrent Head And Neck Squamous Cell Carcinoma
Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Therapy area: Ophthalmology. Indication: Open-Angle Glaucoma
Therapy area: Oncology. Indication: Small-Cell Lung Cancer